<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27590181</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>05</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1744-8409</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Expert review of clinical immunology</Title>
          <ISOAbbreviation>Expert Rev Clin Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Kawasaki disease: etiopathogenesis and novel treatment strategies.</ArticleTitle>
        <Pagination>
          <StartPage>247</StartPage>
          <EndPage>258</EndPage>
          <MedlinePgn>247-258</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/1744666X.2017.1232165</ELocationID>
        <Abstract>
          <AbstractText>Kawasaki disease is an acute febrile systemic vasculitis that predominantly occurs in children below five years of age. Its etiopathogenesis is still not clear, but it is thought to be a complex interplay of genetic factors, infections and immunity. Areas covered: This review article discusses in detail Kawasaki disease, with particular emphasis on the recent updates on its pathogenesis and upcoming alternate treatment options. Though self-limiting in many cases, it can lead to severe complications like coronary artery aneurysms and thrombo-embolic occlusions, and hence requires early diagnosis and urgent attention to avoid them. Intravenous immunoglobulin (IVIG) with or without aspirin has remained the sole treatment option for these cases, but 10-15% cases develop resistance to this treatment. Expert commentary: There is a need to develop additional treatment strategies for children with Kawasaki disease. Targeting different steps of pathogenesis could provide us with alternate therapeutic options.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Agarwal</LastName>
            <ForeName>Shreya</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Clinical &amp; Translational Science , Creighton University School of Medicine , Omaha , NE , USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Agrawal</LastName>
            <ForeName>Devendra K</ForeName>
            <Initials>DK</Initials>
            <AffiliationInfo>
              <Affiliation>a Department of Clinical &amp; Translational Science , Creighton University School of Medicine , Omaha , NE , USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 HL112597</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL116042</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL120659</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>09</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Expert Rev Clin Immunol</MedlineTA>
        <NlmUniqueID>101271248</NlmUniqueID>
        <ISSNLinking>1744-666X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>R16CO5Y76E</RegistryNumber>
          <NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059647" MajorTopicYN="N">Gene-Environment Interaction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009080" MajorTopicYN="N">Mucocutaneous Lymph Node Syndrome</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012075" MajorTopicYN="N">Remission, Spontaneous</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Coronary artery aneurysm</Keyword>
        <Keyword MajorTopicYN="Y">Kawasaki disease</Keyword>
        <Keyword MajorTopicYN="Y">intravenous immunoglobulin</Keyword>
        <Keyword MajorTopicYN="Y">refractory Kawasaki disease</Keyword>
        <Keyword MajorTopicYN="Y">thrombo-embolic occlusion</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>9</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>6</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>9</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27590181</ArticleId>
        <ArticleId IdType="mid">NIHMS885597</ArticleId>
        <ArticleId IdType="pmc">PMC5542821</ArticleId>
        <ArticleId IdType="doi">10.1080/1744666X.2017.1232165</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kontopoulou T, Kontopoulous DG, Vaidakis E, Mousoulis GP. Adult Kawasai disease in a European patient: a case report and review of literature. J Med Case Rep. 2015;9:75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4403952</ArticleId>
            <ArticleId IdType="pubmed">25890055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexoudi I, Kanakis M, Kapsimali V, Vaiopoulos G.  Autoimmun Rev. 9. Vol. 10. Elsevier B.V.; 2011. Kawasaki disease: Current aspects on aetiopathogenesis and therapeutic management; pp. 544–7. Internet. Available from:  http://dx.doi.org/10.1016/j.autrev.2011.04.005 This article provides detailed information about the factors associated with pathogenesis and treatment of Kawasaki disease, as well as ongoing trials for the newer therapeutic options being explored.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2011.04.005</ArticleId>
            <ArticleId IdType="pubmed">21549860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo MMH, Tseng WN, Ko CH, Pan HM, Hsieh KS, Kuo HC. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease. Allergy. 2015;70(3):310–8. Internet. Available from:  http://www.ncbi.nlm.nih.gov/pubmed/25585854.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25585854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uehara R, Belay ED. Epidemiology of Kawasaki Disease in Asia, Europe, and the United States. J Epidemiol. 2012;22(2):79–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3798585</ArticleId>
            <ArticleId IdType="pubmed">22307434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh S, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. Arch Dis Child. 2015;100(11):1084–8. Internet. Available from:  http://www.ncbi.nlm.nih.gov/pubmed/26111818 This article has dicussed in detail the epidemiological characteristics of Kawasaki disease in different parts of the world.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26111818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greco A, De Virgilio A, Rizzo MI, Tombolini M, Gallo A, Fusconi M, et al.   Autoimmun Rev. 8. Vol. 14. Elsevier B.V; 2015. Kawasaki disease: An evolving paradigm; pp. 703–9. Internet. Available from:  http://dx.doi.org/10.1016/j.autrev.2015.04.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2015.04.002</ArticleId>
            <ArticleId IdType="pubmed">25882057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi K, Oharaseki T, Yokouchi Y. Update on etio and immunopathogenesis of Kawasaki disease. Curr Opin Rheumatol. 2014;26(1):31–6. Internet. Available from:  http://www.ncbi.nlm.nih.gov/pubmed/24247115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24247115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luca NJ, Yeung RS. Epidemiology and management of Kawasaki disease. Drugs. 2012;72(8):1029–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22621692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin MC, Lai MS, Jan SL, Fu YC.  J Chinese Med Assoc. 2. Vol. 78. Elsevier Taiwan LLC and the Chinese Medical Association; 2015. Epidemiologic features of Kawasaki disease in acute stages in Taiwan, 1997-2010: Effect of different case definitions in claims data analysis; pp. 121–6. Internet. Available from:  http://dx.doi.org/10.1016/j.jcma.2014.03.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcma.2014.03.009</ArticleId>
            <ArticleId IdType="pmc">PMC7105041</ArticleId>
            <ArticleId IdType="pubmed">25636582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holman RC, Christensen KY, Belay ED, Steiner CA, Effler PV, Miyamura J, et al.  Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. Hawaii Med J. 2010;69(8):194–7. Internet. Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3118023&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3118023</ArticleId>
            <ArticleId IdType="pubmed">20845285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Makino N, Nakamura Y, Yashiro M, Ae R, Tsuboi S, Aoyama Y, et al.  Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012: from the results of the 22nd nationwide survey. J Epidemiol. 2015;25(3):239–45. Internet. Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4341001&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4341001</ArticleId>
            <ArticleId IdType="pubmed">25716368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss PF. Pediatric vasculitis. Pediatr Clin North Am. 2012;59(2):407–23. Internet. Available from:  http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=22560577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3348547</ArticleId>
            <ArticleId IdType="pubmed">22560577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bayers S, Shulman ST, Paller AS. Kawasaki disease: Part I. Diagnosis, clinical features, and pathogenesis. J Am Acad Dermatol. 2013;69(4):501, e1–501.e11. Internet. Available from:  http://dx.doi.org/10.1016/j.jaad.2013.07.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2013.07.002</ArticleId>
            <ArticleId IdType="pubmed">24034379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuo HC, Yang KD, Chang WC, Ger LP, Hsieh KS.  Pediatr Neonatol. 1. Vol. 53. Elsevier Taiwan LLC; 2012. Kawasaki disease: an update on diagnosis and treatment; pp. 4–11. Internet. Available from:  http://www.ncbi.nlm.nih.gov/pubmed/22348488.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22348488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel RM, Shulman ST. Kawasaki disease: a comprehensive review of treatment options. J Clin Pharm Ther. 2015;40(6):620–5. Internet. Available from:  http://doi.wiley.com/10.1111/jcpt.12334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jcpt.12334</ArticleId>
            <ArticleId IdType="pubmed">26547265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scuccimarri R.  Pediatr Clin North Am. 2. Vol. 59. Elsevier Inc; 2012. Kawasaki Disease; pp. 425–45. Internet. Available from:  http://dx.doi.org/10.1016/j.pcl.2012.03.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pcl.2012.03.009</ArticleId>
            <ArticleId IdType="pubmed">22560578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dimitriades VR, Brown AG, Gedalia A. Kawasaki disease: Pathophysiology, clinical manifestations, and management. Curr Rheumatol Rep. 2014;16(6):423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24744086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tseng HC, Ho JC, Guo MMH, Lo MH, Hsieh KS, Tsai WC, et al.  Bull's eye dermatoscopy pattern at bacillus Calmette-Guérin inoculation site correlates with systemic involvements in patients with Kawasaki disease. J Dermatol. 2016:1–7. Internet. Available from:  http://doi.wiley.com/10.1111/1346-8138.13315.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1346-8138.13315</ArticleId>
            <ArticleId IdType="pubmed">26935002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al.  Kawasaki Disease A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association Endorsed by the American Academy of Pediatrics. 2004;114(6):1708–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15574639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ha KS, Lee J, Jang GY, Lee JH, Lee KC, Son CS, et al.  Value of Neutrophil-Lymphocyte Ratio in Predicting Outcomes in Kawasaki Disease. Am J Cardiol. 2015;116(2):301–6. Internet. Available from:  http://dx.doi.org/10.1016/j.amjcard.2015.04.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjcard.2015.04.021</ArticleId>
            <ArticleId IdType="pubmed">25975725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parthasarathy P, Agarwal A, Chawla K, Tofighi T, Mondal TK. Upcoming biomarkers for the diagnosis of Kawasaki disease: A review. Clin Biochem. 2015;48(16–17):1188–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25749557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin KH, Chang SS, Yu CW, Lin SC, Liu SC, Chao HY, et al.  Usefulness of natriuretic peptide for the diagnosis of Kawasaki disease: a systematic review and meta-analysis. BMJ Open. 2015;5(4):e006703. Internet. Available from:  http://bmjopen.bmj.com/content/5/4/e006703.full.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4401842</ArticleId>
            <ArticleId IdType="pubmed">25872939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye Q, Shao WX, Shang SQ, Zhang T, Hu J, Zhang CC. A comprehensive assessment of the value of laboratory indices in diagnosing Kawasaki disease. Arthritis Rheumatol. 2015;67(7):1943–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25778686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dietz SM, Tacke CE, Kuipers IM, Wiegman A, de Winter RJ, Burns JC, et al.  Cardiovascular imaging in children and adults following Kawasaki disease. Insights Imaging. 2015;6(6):697–705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4656233</ArticleId>
            <ArticleId IdType="pubmed">26210915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tacke CE, Kuipers IM, Groenink M, Spijkerboer AM, Kuijpers TW. Cardiac magnetic resonance imaging for noninvasive assessment of cardiovascular disease during the follow-up of patients with kawasaki disease. Circ Cardiovasc Imaging. 2011;4(6):712–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21921132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mavrogeni S, Papadopoulos G, Hussain T, et al.  Int J Cardiovasc Imaging. 2013;29(8):1787–1798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23949280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KY, Kim DS. Recent Advances in Kawasaki Disease. Yonsei Med J. 2016;57(1):15–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4696947</ArticleId>
            <ArticleId IdType="pubmed">26632378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv YW, Wang J, Sun L, Zhang JM, Cao L, Ding YY, et al.  Understanding the pathogenesis of Kawasaki disease by network and pathway analysis. Comput Math Methods Med. 2013;2013:17–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3606754</ArticleId>
            <ArticleId IdType="pubmed">23533546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoon KL. Update of genetic susceptibility in patients with kawasaki disease. Korean J Pediatr. 2015;58(3):84–8. This study presented the results from Genome Wide Association Studies indicating the role of various possible genes in susceptibility to Kawasaki disease.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4388975</ArticleId>
            <ArticleId IdType="pubmed">25861330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onouchi Y, Gunji T, Burns JC, Shimizu C, Jane W, Fukushima Y, et al.  ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008;40(1):35–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2876982</ArticleId>
            <ArticleId IdType="pubmed">18084290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Lou J, Zhong R, Qi Y, Shen N, Lu X, et al.  The roles of Ca2+/NFAT signaling genes in Kawasaki disease: single- and multiple-risk genetic variants. Sci Rep. 2014;4:5208. Internet. Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4047536&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4047536</ArticleId>
            <ArticleId IdType="pubmed">24903211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onouchi Y, Ozaki K, Buns JC, Shimizu C, Hamada H, Honda T, et al.  Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum Mol Genet. 2010;19(14):2898–906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2893807</ArticleId>
            <ArticleId IdType="pubmed">20423928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onouchi Y. Genetics of Kawasaki disease: what we know and don't know. Circ J. 2012;76(7):1581–6. Internet. Available from:  http://www.ncbi.nlm.nih.gov/pubmed/22789975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22789975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimizu C, Jain S, Davila S, Hibberd ML, Lin KO, Molkara D, et al.  Transforming Growth Factor-β Signaling Pathway in Patients With Kawasaki Disease. Circ Cardiovasc Genet. 2011;4(1):16–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3073847</ArticleId>
            <ArticleId IdType="pubmed">21127203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yim D, Curtis N, Cheung M, Burgner D. Update on Kawasaki disease: Epidemiology, aetiology and pathogenesis. J Paediatr Child Health. 2013;49(9):704–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23560706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galeotti C, Bayry J, Kone-Paut I, Kaveri SV.  Autoimmun Rev. 6. Vol. 9. Elsevier B.V; 2010. Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin; pp. 441–8. Internet. Available from:  http://dx.doi.org/10.1016/j.autrev.2009.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2009.12.004</ArticleId>
            <ArticleId IdType="pmc">PMC7185630</ArticleId>
            <ArticleId IdType="pubmed">20004744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee KY, Han JW, Lee JS. Kawasaki disease may be a hyperimmune reaction of genetically susceptible children to variants of normal environmental flora. Med Hypotheses. 2007;69(3):642–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7117004</ArticleId>
            <ArticleId IdType="pubmed">17337130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagao Y, Urabe C, Nakamura H, Hatano N. Predicting the characteristics of the aetiological agent for Kawasaki disease from other paediatric infectious diseases in Japan. Epidemiol Infect. 2016;144(3):478–92. Internet. Available from:  http://www.journals.cambridge.org/abstract_S0950268815001223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4714300</ArticleId>
            <ArticleId IdType="pubmed">26201398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsubara K, Fukaya T, Miwa K. Development of serum IgM antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogenes in Kawasaki disease. 2006;143(3):427–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1809617</ArticleId>
            <ArticleId IdType="pubmed">16487241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang CL, Wu YT, Liu CA, Kuo HC, Yang KD. Kawasaki Disease. Pediatr Infect Dis J. 2005;24(11):998–1004. Internet. Available from:  http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&amp;an=00006454-200511000-00015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16282937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee MN, Cha JH, Ahn HM, Yoo JH, Kim HS, Sohn S, et al.  Mycoplasma pneumoniae infection in patients with Kawasaki disease. Korean J Pediatr. 2011;54(3):123–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3120998</ArticleId>
            <ArticleId IdType="pubmed">21738542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Usta Guc B, Cengiz N, Yildirim SV, Uslu Y. Cytomegalovirus infection in a patient with atypical Kawasaki disease. Rheumatol Int. 2008;28(4):387–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7079931</ArticleId>
            <ArticleId IdType="pubmed">17717671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang LY, Lu CY, Shao PL, Lee PI, Lin MT, Fan TY, et al.  Viral infections associated with Kawasaki disease. J Formos Med Assoc. 2014;113(3):148–54. Internet. Available from:  http://www.ncbi.nlm.nih.gov/pubmed/24495555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7125523</ArticleId>
            <ArticleId IdType="pubmed">24495555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bajolle F, Meritet JF, Rozenberg F, Chalumeau M, Bonnet D, Gendrel D, et al.  Markers of a recent bocavirus infection in children with Kawasaki disease: “A year prospective study”. Pathol Biol. 2014;62(6):365–8. Internet. Available from:  http://dx.doi.org/10.1016/j.patbio.2014.06.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.patbio.2014.06.002</ArticleId>
            <ArticleId IdType="pubmed">25193448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, et al.  ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008;40(1):35–42. Internet. Available from:  http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2876982&amp;tool=pmcentrez&amp;rendertype=abstract.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2876982</ArticleId>
            <ArticleId IdType="pubmed">18084290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J. Evaluation of Intravenous Immunoglobulin Resistance and Coronary Artery Lesions In Relation to Th1 / Th2 Cytokine Profiles in Patients With Kawasaki Disease. Arthritis Rhuem. 2013;65(3):805–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23440694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia S, Li C, Wang G, Yang J, Zu Y. The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease. Clin Exp Immunol. 2010;162(1):131–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2990938</ArticleId>
            <ArticleId IdType="pubmed">20718783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ni CR, Li Q, Xia Y, Wang GB, Yang J, FF L. Regulatory T cell microRNA expression changes in children with acute Kawasaki disease. Clin Exp Immunol. 2014;178:384–93. Internet. Available from:  http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=reference&amp;D=medc&amp;NEWS=N&amp;AN=25039241 http://onlinelibrary.wiley.com/doi/10.1111/cei.12418/abstract.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.12418/abstract</ArticleId>
            <ArticleId IdType="pmc">PMC4233387</ArticleId>
            <ArticleId IdType="pubmed">25039241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuo HC, Yang KD, Juo SHH, Liang CDi, Chen WC, Wang YS, et al.  Itpkc single nucleotide polymorphism associated with the kawasaki disease in a taiwanese population. PLoS One. 2011;6(4):2–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3077380</ArticleId>
            <ArticleId IdType="pubmed">21533171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ge X, Li CR, Yang J, Wang GB. Aberrantly Decreased Levels of NKG2D Expression in Children with Kawasaki Disease. Scand J Immunol. 2013;77(5):389–97. This article provides evidence to the role of NKG2D in causation of Kawasaki disease and the associated coronary artery lesions.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23298273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee Y, Wakita D, Dagvadorj J, Shimada K, Chen S, Huang G, et al.  IL-1 Signaling Is Critically Required in Stromal Cells in Kawasaki Disease Vasculitis Mouse Model: Role of Both IL-1α and IL-1β. Arterioscler Thromb Vasc Biol. 2015;35(12):2605–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4662607</ArticleId>
            <ArticleId IdType="pubmed">26515418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tremoulet AH, Jain S, Kim S, Newburger J, Arditi M, Franco A, Best B, Burns JC. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial) Contemp Clin Trials. 2016;48:70–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5221485</ArticleId>
            <ArticleId IdType="pubmed">27080929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song R, Liu G, Li X, Xu W, Liu J, Jin H. Elevated Inducible Nitric Oxide Levels and Decreased Hydrogen Sulfide Levels Can Predict the Risk of Coronary Artery Ectasia in Kawasaki Disease. Pediatr Cardiol. 2015;37(8):322–9. Internet. Available from:  http://dx.doi.org/10.1007/s00246-015-1280-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00246-015-1280-8</ArticleId>
            <ArticleId IdType="pubmed">26499359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao-hui LI, Chao-ying Z, Jian-xin WU, Ting Z, General M, et al.  Committee E. Changes in plasma hydrogen sulfide and nitric oxide levels and. Chinese Med J. 2011;124(21):3445–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22340156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang CL, Wu YT, Lee CJ, Liu HC, Huang LT, Yang KD. Decreased nitric oxide production after intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2002;141(4):560–5. Internet. Available from:  http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=12378198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12378198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayward K, Wallace Ca, Koepsell T. Perinatal exposures and Kawasaki disease in Washington State: a population-based, case-control study. Pediatr Infect Dis J. 2012;31(10):1027–31. Internet. Available from:  http://www.ncbi.nlm.nih.gov/pubmed/22653485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22653485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al.  Diagnosis, treatment, and long term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis amd Kawasaki disease, Council on Cardiovascular Disease in the Young,American Heart Association. 2004;110(17):2747–71. It has provided the nationally accepted guidelines for the diagnosis and management of patients with Kawasaki disease.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15505111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuo HC, Hsu YW, Wu MS, Chien SC, Liu SF, Chang WC.  J Microbiol Immunol Infect. 1. Vol. 49. Elsevier Taiwan LLC; 2016. Intravenous immunoglobulin, pharmacogenomics, and Kawasaki disease; pp. 1–7. Internet. Available from:  http://linkinghub.elsevier.com/retrieve/pii/S1684118214002278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25556045</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bayers S, Shulman ST, Paller AS.  J Am Acad Dermatol. 4. Vol. 69. Elsevier Inc; 2013. Kawasaki disease: Part II. Complications and treatment; pp. 513.e1–513.e8. Internet. Available from:  http://dx.doi.org/10.1016/j.jaad.2013.06.040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2013.06.040</ArticleId>
            <ArticleId IdType="pubmed">24034380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsieh K, Weng K, Lin C, Huang T, Lee C, Huang S. Treatment of Acute Kawasaki Disease : Aspirin ' s Role in the Febrile stage revisited. Pediatrics. 2004;114(6):e689–693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15545617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shulman ST. Management of Kawasaki disease. J Pediatr. 1988;113(6):1116–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3193319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muta H, Ishii M, Yashiro M, Uehara R, Nakamura Y. Late Intravenous Immunoglobulin Treatment in Patients With Kawasaki Disease. Pediatrics. 2012;129(2):e291–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22250032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowley AH. The Complexities of the Diagnosis and Management of Kawasaki Disease. Infect Dis Clin North Am. 2015;29(3):525–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4552602</ArticleId>
            <ArticleId IdType="pubmed">26154665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujimaru T, Ito S, Masuda H, Oana S, Kamei K, Ishiguro A, et al.   Cytokine. 2. Vol. 70. Elsevier Ltd; 2014. Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange; pp. 156–60. Internet. Available from:  http://dx.doi.org/10.1016/j.cyto.2014.07.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2014.07.003</ArticleId>
            <ArticleId IdType="pubmed">25082649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahbarimanesh A, Taghavi-goodarzi M. Comparison of High-Dose versus Low-Dose Aspirin in the Management of Kawasaki Disease. Indian J Pediatr. 2014;81(December):12098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24710712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Portman MA, Olson A, Soriano B, Dahdah N, Williams R, Kirkpatrick E. Etanercept as adjunctive treatment for acute kawasaki disease: Study design and rationale. Am Heart J. 2011;161(3):494–9. Internet. Available from:  http://dx.doi.org/10.1016/j.ahj.2010.12.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ahj.2010.12.003</ArticleId>
            <ArticleId IdType="pubmed">21392603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics. 1979;63(2):175–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">440805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adachi S, Sakaguchi H, Kuwahara T, Uchida Y, Fukao T, Kondo N. High regression rate of coronary anuerysms developed in patients with immune globulin resistant Kawasaki disease treated with steroid pulse therapy. Tohoku J Exp Med. 2010;220(4):285–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20410679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, et al.  Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open label, blinded-endpoints trial. Lancet. 2012;379(9826):1613–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22405251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saneeymehri S, Baker K, So TY. Overview of Pharmacological Treatment Options for Pediatric Patients with Refractory Kwasaki Disease. J Pediatr Pharmacol Ther. 2015;20(3):163–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4471710</ArticleId>
            <ArticleId IdType="pubmed">26170768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M. Corticosteroid Pulse Combination Therapy for Refractory Kawasaki Disease: A Randomized Trial. Pediatrics. 2012;129(1):e17–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22144699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart. 2012:76–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22869678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weng KP, Ou SF, Lin CC, Hsieh KS. Recent advances in the treatment of Kawasaki disease. J Chin Med Assoc. 2011;74(11):481–4. Internet. Available from:  http://www.ncbi.nlm.nih.gov/pubmed/22100015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22100015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miura M, Ohki H, Yoshiba S, Ueda H, Sugaya A, Satoh M, Yamagishi H. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child. 2005;90(10):1096–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1720131</ArticleId>
            <ArticleId IdType="pubmed">16177169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu JJ. Use of corticosteroids during acute phase of Kawasaki disease. World J Clin Pediatr. 2015;4(4):135. Internet. Available from:  http://www.wjgnet.com/2219-2808/full/v4/i4/135.htm.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4637804</ArticleId>
            <ArticleId IdType="pubmed">26566486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim YJ, Jung JW. Clinical Outcomes of Initial Dexamethasone Treatment Combined with a Single High Dose of Intravenous Immunoglobulin for Primary Treatment of Kawasaki Disease. 2014;55(5):1260–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4108810</ArticleId>
            <ArticleId IdType="pubmed">25048483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, et al.  Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: Report of an open-label case series. J Rheumatol. 2012;39(4):864–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22337241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, et al.   Lancet. 9930. Vol. 383. Elsevier Ltd; 2014. Infliximab for intensification of primary therapy for Kawasaki disease: A phase 3 randomised, double-blind, placebo-controlled trial; pp. 1731–8. Internet. Available from:  http://dx.doi.org/10.1016/S0140-6736(13)62298-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(13)62298-9</ArticleId>
            <ArticleId IdType="pubmed">24572997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams RV, Wilke VM, Tani LY, Minich LL. Objective A, Kawasaki A. Does Abciximab Enhance Regression of Coronary Aneurysms Resulting From Kawasaki Disease? 2002;109(1)</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11773572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choueiter NF, Olson AK, Shen DD, Portman MA. A prospective open label trial of etanercept as adjunctive Therapy for Kawasaki Disease. J Pediatr. 2010;157(6):960–966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2970727</ArticleId>
            <ArticleId IdType="pubmed">20667551</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori M, Imagawa T, Katakura S, Miyamae T, Okuyama K, Ito S, Nakamura T, Kimura H, Yokota S. Efficacy of plasma exhange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol. 2004;14(1):43–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17028804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsui M, Okuma Y, Yamanaka J, Uryu H, Sato N, Shichino H, et al.   Cytokine. 2. Vol. 74. Elsevier Ltd; 2015. Kawasaki disease refractory to standard treatments that responds to a combination of pulsed methylprednisolone and plasma exchange: Cytokine profiling and literature review; pp. 339–42. Internet. Available from:  http://dx.doi.org/10.1016/j.cyto.2015.02.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cyto.2015.02.014</ArticleId>
            <ArticleId IdType="pubmed">25801094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonoda K, Mori M, Hokosaki T, Yokota S.  J Pediatr. 5. Vol. 164. Elsevier Ltd; 2014. Infliximab plus plasma exchange rescue therapy in Kawasaki disease; pp. 1128–1132.e1. Internet. Available from:  http://dx.doi.org/10.1016/j.jpeds.2014.01.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpeds.2014.01.020</ArticleId>
            <ArticleId IdType="pubmed">24560183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tremoulet AH, Pancoast P, Franco A, Bujold M, Shimizu C, Onouchi Y, et al.  Calcineurin inhibitor treatment of intravenous immunoglubulin resistant Kawasaki disease. J Pediatr. 2012;161(3):506–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3613150</ArticleId>
            <ArticleId IdType="pubmed">22484354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuijpers TW, Biezeveld M, Achterhuis A, Kuipers I, Lam J, Hack CE, et al.  Longstanding obliterative panarteritis in Kawasaki disease: lack of cyclosporin A effect. Pediatrics. 2003;112(4):986–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14523200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki h, Terai M, Hamada H, Honda T, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, et al.  Cyclosporin A treatment for kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J. 2011;30(10):871–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21587094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aoyagi R, Hamada H, Sato Y, Suzuki H, Onouchi Y, Ebata R, et al.  Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial) BMJ Open. 2015;5(12):e009562. Internet. Available from:  http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2015-009562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2015-009562</ArticleId>
            <ArticleId IdType="pmc">PMC4679944</ArticleId>
            <ArticleId IdType="pubmed">26628527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodrigues-Diez R, González-Guerrero C, Ocaña-Salceda C, Rodrigues-Diez RR, Egido J, Ortiz A, et al.   Sci Rep. May. Vol. 6. Nature Publishing Group; 2016. Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling; p. 27915. Internet. Available from:  http://www.ncbi.nlm.nih.gov/pubmed/27295076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4904742</ArticleId>
            <ArticleId IdType="pubmed">27295076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-homsi AS, Roy TS, Cole K, Feng Y, Duffner U.  Biol Blood Marrow Transplant. 4. Vol. 21. Elsevier Inc; 2015. Biology of Blood and Marrow Transplantation Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease; pp. 604–11. Internet. Available from:  http://dx.doi.org/10.1016/j.bbmt.2014.08.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbmt.2014.08.014</ArticleId>
            <ArticleId IdType="pubmed">25240817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Falcini F. Kawasaki disease. Curr Opin Rheumatol. 2006;18(1):33–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16344617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong PT, Choi SK. Mechanisms and Implications of Dual-Acting Methotrexate in Folate-Targeted Nanotherapeutic Delivery. Int J Mol Sci. 2015;16(1):1772–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4307333</ArticleId>
            <ArticleId IdType="pubmed">25590303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee MS, An SY, Jang GC, Kim DS. A case of intravenous immunoglobulin resistant Kawasaki disease treated with methotrexate. Yonsei Med J. 2002;43(4):527–532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12205742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee TJ, Kim KH, Chun JK, Kim DS. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J. 2008;49(5):714–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2615375</ArticleId>
            <ArticleId IdType="pubmed">18972590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim NY, Choi DY, Jung MJ, Jeon IS. A case of refractory Kawasaki disease complicated by peripheral ischemia. Pediatr Cardiol. 2008;29(6):1110–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18481137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Magalhães CMR, Alves NR, de Melo AV, Silveira Junior CA, Nobrega YK, Gandolfi L, et al.  Catastrophic Kawasaki disease unresponsive to IVIG in a 3-month-old infant: a diagnostic and therapeutic challenge. Pediatr Rheumatol Online J. 2012;10:28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3598686</ArticleId>
            <ArticleId IdType="pubmed">22929725</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
